US Patent

US11154509 — Methods for controlled release oral dosage of a vitamin D compound

Method of Use · Assigned to Eirgen Pharma Ltd · Expires 2028-04-25 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for preparing a controlled release oral dosage form of a vitamin D compound using a mixture of waxy materials.

USPTO Abstract

A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.

Drugs covered by this patent

Rayaldee (CALCIFEDIOL)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3815`	—	Rayaldee

Patent Metadata

Patent number: US11154509
Jurisdiction: US
Classification: Method of Use
Expires: 2028-04-25
Drug substance claim: No
Drug product claim: No
Assignee: Eirgen Pharma Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.